Black­Rock joins An­drew Lo's risk analy­sis firm to search for odds-on biotech bets in tur­bu­lent times

MIT fi­nance pro­fes­sor An­drew Lo has more in­sid­er con­nec­tions than just about any oth­er aca­d­e­m­ic play­er you’ll find in any in­dus­try. And to­day, if you val­ued his biotech con­nec­tions in fi­nan­cial terms, it just spiked.

Lo’s QLS Ad­vi­sors LLC (that stands for Quan­ti­ta­tive Life Sci­ences) has just joined forces with Black­Rock Sys­tem­at­ic. To put it sim­ply, Lo’s QLS will now put its ma­chine learn­ing ap­proach to de­ter­min­ing drug de­vel­op­ment risk to work with Black­Rock ex­ecs to guide their tar­get­ed strat­e­gy for find­ing biotech win­ners.

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.

UPGRADE